Alzheimer Data Good for NeoTherapeutics
NeoTherapeutics Inc. said clinical data from a study of its nerve-regeneration drug Neotrofin showed the treatment facilitates brain activity in Alzheimer’s disease patients.
The Irvine biopharmaceutical company said the study, which treated 19 patients with Neotrofin, resulted in significant improvement in memory, attention and judgment.
The improvement also was greater as the doses increased, with 500-milligram and 1,000-milligram doses producing statistically better results than a 150-milligram dose, the company said. Neotrofin didn’t cause any serious side effects.
NeoTherapeutics said another phase of U.S. and global clinical trials are being designed. After the company reaches an agreement with the Food and Drug Administration on the protocol early next year, it will begin enrolling patients.
The stock closed at $4.94, off 6 cents a share, in Nasdaq trading.
More to Read
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
